Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179216 | 0.84 | KDM4E (0.45) | GRM5KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL901915 | 0.84 | GRM5 (0.46) | GRM5VCAM1MEN1KMT2A | |
| SCHEMBL1043930 | 0.78 | SMN1; SMN2 (0.38) | GRM5KDM4ELMNAADORA2AALDH1A1 | |
| SCHEMBL16976904 | 0.76 | KDM4E (0.39) | GRM5KDM4EMEN1KMT2A | |
| SCHEMBL13045682 | 0.74 | GRM5 (0.41) | GRM5VCAM1MEN1KMT2A | |
| SCHEMBL27919228 | 0.74 | TTR (0.45) | GRM5KDM4ELMNAMEN1KMT2A | |
| SCHEMBL18297112 | 0.74 | LMNA (0.41) | GRM5KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL4930877 | 0.74 | MEN1 (0.40) | GRM5KDM4ELMNAMEN1KMT2A | |
| SCHEMBL11620108 | 0.74 | GRM5 (0.41) | GRM5VCAM1 | |
| SCHEMBL955626 | 0.74 | NOS3 (0.52) | GRM5KDM4EALDH1A1HPGDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| CN-115916765-B | Pyridine or pyrimidine derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION | 2025-03-06 | — | — | US | disclosed |
| WO-2024156938-A1 | CBL-B INHIBITORS | ORION CORPORATION (FI) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024059204-A1 | HETEROARYL ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3983383-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20080161365-A1 | e.g. 4-{3-fluoro-3-[2-methyl-6-(3-trifluoromethyl-benzylcarbamoyl)-pyridin-4-yl]-propyl}-benzoic acid; collagenases inhibitor; osteoarthritis or rheumatoid arthritis, heart failure, breast cancer metastasis, and other diseases that are mediated by MMP-13 overactivity | PFIZER INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | disclosed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161365-A1 | e.g. 4-{3-fluoro-3-[2-methyl-6-(3-trifluoromethyl-benzylcarbamoyl)-pyridin-4-yl]-propyl}-benzoic acid; collagenases inhibitor; osteoarthritis or rheumatoid arthritis, heart failure, breast cancer metastasis, and other diseases that are mediated by MMP-13 overactivity | MMP13, MMP9, MMP11 | GRM5 2575/4885KDM4E 521/4885VCAM1 2028/4885 |
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | CDK2, CDK20, CDK2AP1 | GRM5 3937/4885KDM4E 1754/4885VCAM1 2852/4885 |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | GRM5 1018/4885KDM4E 3667/4885VCAM1 2788/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | GRM5 952/4885KDM4E 4309/4885VCAM1 3842/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | GRM5 1334/4885KDM4E 4082/4885VCAM1 3540/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | GRM5 459/4885KDM4E 1355/4885VCAM1 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.